spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

European Pharmaceutical Contractor (EPC) is designed to fill a unique position in pharmaceutical publishing. Providing a dedicated platform of communication and information for the international pharmaceutical contract market, it consists of a series of articles and case studies written by eminent figures in contractor groups and traditional multinational pharmaceutical companies.

Each quarterly edition examines areas of importance – both economic and technical – to contract research organisations, contract manufacturers, regulatory controllers, consultants and analysts. This enables regulatory bodies to link directly with policy-makers both in major contractor groups and pharmaceutical companies, and thereby convey regulatory information directly from the governing bodies, but also ensure debate between the policy-makers and consultancy groups.

 

For further information please contact:

Advertising
Jonathan Smith

Editorial
Charlie Burgon

We're also on Twitter! Follow us @EPCmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


View the digital version of EPC




 

epc
 
 
Featured in this issue
The introduction
Editor’s Letter

Graham Hughes homes in on the theme of patient protection in this issue, and discusses the features that have a regional focus.
Regional Focus
Clinical Research: Turkey

Land of Opportunity


At the centre of an emerging region, Turkey boasts a supportive regulatory framework, a large number of sites and diverse patients, and a competive cost structure. Ömer Sadun Okyaltırık and Yamin Khan of Pharm-Olam report.

  Legal & Regulatory
Anti-Bribery and Corruption

Prevention is Better Than Cure

If adequate defences are not implemented to prevent bribery, a company can be charged despite having no prior knowledge of an offence. Therefore, as Catriona Munro of Maclay Murray & Spens LLP underlines, pharma must be seen to be doing everything it can to avert such incidents.

spacer
Edited by
Dr Graham Hughes,
Consultant in
Pharmaceutical
Development
Published quarterly in
March, June,
September and December
Banner of Medical Research Network (MRN) Limited on Samedan
Banner of ESMO.EPC on Samedan
Banner of Inform.EPC on Samedan
 
Industry Events

10th Annual Cold Chain Distribution Conference and Exhibition

3-4 December 2015, Victoria Park Plaza, London, UK

This year’s Cold Chain Distribution is the must attend event providing hours of networking with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding the global healthcare cold chain distribution process and logistic requirements for various temperature-sensitive healthcare products. Last year’s conference was sold out – make sure you register as soon as possible to secure your seat! Event website: http://www.coldchain-distribution.com/samedan. First 20 pharma companies to register receive a special £899 rate. Subject to availability.
More info >>

 
News and Press Releases

SHL Group introduces new Corporate Website

To enhance the user experience of their corporate website, and to better support their group companies (including SHL Medical, SHL Healthcare, SHL Technologies and SHL Pharma), SHL Group are proud to introduce their newest corporate website.
More info >>

Banner of Drug Delivery Congress on Samedan
air transport logo

 

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement